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Inflammatory myofibroblastic tumors (IMTs) and gastrointestinal stromal tumors (GISTs) are both spindle cell
tumors, and occur rarely in the wall of the urinary bladder. In general, immunostaining allows differentiation
of IMTs and GISTs. Most IMTs are positive for anaplastic lymphoma kinase (ALK) and negative for KIT, whereas
most GISTs are ALK-negative and KIT-positive. Here, we describe a case of a spindle cell tumor in the wall of
the urinary bladder. The spindle cells were positive for both ALK and KIT, and it was thus difficult to determine
whether the tumor was an IMT or a GIST. We eventually diagnosed an IMT, because ALK gene rearrangement
was confirmed by fluorescent in-situ hybridization. Cytoplasmic staining for KIT and the absence of other GIST
markers, including DOG1 and platelet-derived growth factor α, indicated that the tumor was not a GIST.
Therefore, IMTs should be included in the differential diagnosis of spindle cell tumors, even those that are
KIT-positive.
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Inflammatory myofibroblastic tumors (IMTs) are spindle
cell tumors sometimes considered to exhibit borderline
malignancy [1]. These tumors are characterized by the
infiltration of inflammatory cells, including lympho-
cytes, plasma cells, and eosinophils [1] and can occur
at any site in the body, including the urinary bladder
[2,3]. Approximately half of all IMTs exhibit anaplastic
lymphoma kinase (ALK) gene rearrangements [4],
which are considered to be an IMT marker, as are ex-
pression of vimentin, muscle-specific actin, and calpo-
nin [5-7]. The majority of IMTs do not express S-100,
KIT, or CD34 [5-7].
A gastrointestinal stromal tumor (GIST) is another
form of spindle cell tumor [8] that rarely occurs in
the urinary bladder [9,10]. Most GISTs exhibit gain-* Correspondence: haga@kuhp.kyoto-u.ac.jp
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reproduction in any medium, provided the orof-function mutations in the KIT gene and express
KIT protein [11,12]. KIT is a receptor-type tyrosine
kinase [13] and is thus usually present in membranes,
but it may also be expressed in the cytoplasm. Some
GISTs lacking KIT mutations have mutations in the
platelet-derived growth factor receptor α (PDGFRα)
gene [14]. In such cases, PDGFRα serves as a GIST
marker [14]. The DOG1 gene is also considered to be
a marker of GIST [15].
Here, we describe a spindle cell tumor that developed in
the wall of the urinary bladder. Immunostaining showed
that the tumor cells were positive for both ALK and KIT
expression, and it was thus difficult to distinguish whether
the tumor was an IMT or GIST.Case presentation
Methods
Immunostaining
The antibodies used are listed in Tables 1 and 2.
Cytological specimens were fixed in 100% methanol,l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
Table 1 Antibodies used for immunostaining in immunocytochemical analyses.
Antigen Clone Dilution Source Pretreatment
SMA 1A4 Prediluted Nichirei None
Desmin D33 Prediluted Nichirei None
Pan-cytokeratin AE1/AE3 Prediluted Nichirei None
KIT Polyclonal 1:25 DAKO None
ALK 5A4 Prediluted Nichirei None
ALK, anaplastic lymphoma kinase.
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and paraffin-embedded. Both types of specimen were
stained, as described in a previous report [16], in
addition to ALK immunohistochemical staining of
pathological specimens, which was performed using
the intercalated antibody-enhanced polymer (iAEP)
method [17].
KIT mutation analysis
The DNA was extracted from pathological specimens.
Exons 11 and 17 of the KIT gene were amplified by PCR
and used for direct sequencing [18].
Fluorescent in-situ hybridization (FISH) examination of ALK
To explore ALK gene rearrangements, fluorescent in-situ
hybridization (FISH) was performed using a Vysis ALK
Break Apart FISH Probe kit (Abbott Molecular, Des
Plaines, IL, USA) [19]. Briefly, unstained sections (4 μm
thick) were subjected to hybridization according to the
manufacturer’s protocol. ALK rearrangement was con-
sidered present when over 15% of the tumor cells dis-
played orange and green hybrid signals or an orange
signal alone.
Clinical history
Our patient was a 31-year-old woman initially admit-











* The iAEP method was required to obtain the signals. ALK, anaplastic lympho
factor receptor.subsequently transferred to our hospital for further
examination. First, we performed a cytological study of
her urine and a cystoscopic examination. The cyto-
logical study did not yield any specific findings, but
cystoscopy detected a submucosal tumor lying beneath
the normal mucosa (Figure 1A). Computed tomog-
raphy and magnetic resonance imaging identified a
mass 4.5 cm in diameter in the right lateral wall of the
urinary bladder (Figure 1B,C). Transurethral resection
of the bladder tumor (TUR-Bt) was performed to ob-
tain a diagnosis. Spindle cells were collected during
TUR-Bt, but they did not yield any diagnostic informa-
tion because of heat denaturation.
We surgically resected the mass (Figure 2), which was
located in the muscular layer of the urinary bladder, and
was thus not contiguous with the mucosa. Imprint cy-
tology was performed during resection (Figure 3A) and
revealed numerous spindle cells with an abundance of
cytoplasm and low nuclear atypia, admixed with infiltrat-
ing lymphocytes. Immunocytochemically, the spindle
cells were negative for smooth muscle actin and desmin,
but an anti-KIT antibody yielded a positive reaction
(Figure 3B). However, the cells were also positive for
ALK (Figure 3C). Histologically, a spindle cell tumor
that was immunohistochemically positive for both KIT
and ALK was also identified (Figure 4A-C). The fact
that the nuclear atypia was of low grade and that agical analyses.
Source Pretreatment
d Nichirei None
d Nichirei Microwave (10 min)
d Nichirei Protease
DAKO Microwave (10 min)
Nichirei Boiling (30 min)*
Santa Cruz Boiling (60 min)
Nichirei Boiling (60 min)
Epitomics Boiling (30 min)
Nichirei Boiling (60 min)
ma kinase; IgG, immunoglobulin G; PDGFR, platelet-derived growth
Figure 1 Cystoscopy, computed tomography, and magnetic resonance imaging findings. (A) Cystoscopy, (B) computed tomography, and
(C) magnetic resonance imaging. White and yellow arrowheads indicate the submucosal tumor in the urinary bladder.
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out sarcomatoid cancer. We also excluded leiomyosar-
coma and rhabdomyosarcoma because the tumor was
negative for smooth muscle actin and desmin. In addition,
staining for IgG and IgG4 indicated that the tumor
was not an IgG4-related inflammatory pseudotumor,
because IgG4-positive cells were very rare. A GIST was
considered in differential diagnosis. We found no muta-
tion in the KIT gene. The tumor cell cytoplasm stained
weakly for KIT, which is unusual (but not unknown) for
GIST tumors [11,12]. In addition, the cells were negative
for other GIST markers (that is, PDGFRα and DOG1)
[14,15]; therefore, we ruled out GIST. To evaluate the
ALK gene status, we performed FISH analysis using
the Vysis ALK Break Apart FISH Probe kit and found
that approximately 20% of the signals indicated ALK
gene rearrangement (Figure 4D). Thus, we diagnosed
the tumor as an IMT.
Our patient is alive and well, without recurrence, 3 years
after resection.
Discussion
Most submucosal tumors in the wall of the urinary
bladder are spindle cell tumors [20,21]. The spindle
cell tumor in our patient expressed ALK. To the bestFigure 2 Macroscopic findings. (A) Halved specimens. (B) Sliced specimeof our knowledge, only one previous report examined
the ALK status of GISTs and found that such tumors
were ALK-negative [22]. However, more evidence is
required to rule out a GIST, even if a spindle cell
tumor is positive for ALK. ALK rearrangement is as-
sociated with the pathogenesis of various malignan-
cies, including anaplastic large-cell lymphoma, non-
small cell lung cancer, and neuroblastoma [23]. In
addition, ALK rearrangement, associated with an al-
tered enzyme expression level, is detected in approxi-
mately half of IMTs [4-7]. In the current case, we
found that a significant proportion of ALK genes were
split (Figure 4D).
Morphological discrimination between IMT and GIST
was nearly impossible in the present case, but we
found that cytological examination was useful in this
context. It was feasible to stain cytological specimens
for ALK, and no pretreatment was required. However,
we had to use a sophisticated method (iAEP method
[19]) to stain the histological specimens (Table 1).
Thus, cytological analysis using ALK immunostaining
might be useful in differentiating an IMT from a
GIST.
A variety of spindle cell tumors exhibit KIT positivity, in-
cluding mesothelioma [24], leiomyosarcoma [24], clear cellns. Bar, 1 cm.
Figure 3 Cytological findings. (A) Papanicolaou staining. (B) KIT staining using a rabbit polyclonal antibody purchased from DAKO. (C) ALK
staining using a monoclonal antibody purchased from Nichirei. All photographs were obtained at 400× magnification.
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[24], angiomyolipoma [25,26], bladder urothelial carcinoma
[24,27], and malignant melanoma [27]. Therefore, KIT
immunopositivity alone cannot differentially diagnose a
GIST among spindle cell tumors. In this case, the KIT
staining pattern and the lack of PDGFRα and DOG1 im-
munoreactivity suggested that a GIST was unlikely.
Eventually, we diagnosed the tumor as a KIT-positive
IMT. Such tumors are rare, with only two cases reported
in the English-language literature [2]. Interestingly, both
tumors were in the urinary bladder [2]. Therefore, KIT
positivity alone might not be adequate to diagnose a
GIST, especially if the tumor is in the urinary bladder.Figure 4 Histological findings. (A) H & E staining. (B) KIT staining using a
using a monoclonal antibody purchased from Nichirei. (D) FISH analysis us
indicate signals positive for ALK gene rearrangements. All photographs werConclusions
A possibility of IMT should be included in the differ-
ential diagnosis of KIT-positive spindle cell tumors,
especially those in the urinary bladder. Molecular ex-
ploration of ALK rearrangements and KIT mutations
may be required to diagnose KIT-positive spindle cell
tumors.Consent
Our patient kindly provided written informed consent
for publication of this case report and the accompanying
images.rabbit polyclonal antibody purchased from DAKO. (C) ALK staining
ing the Vysis ALK Break Apart FISH Probe kit. White arrowheads
e obtained at 200× magnification.
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